Major Product Segments Analyzed Are Blood Growth Factors, And Tissue Growth Factors inside New...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41501) has announced the addition of Growth Factors (Blood and Tissue) - Global Strategic Business Report to their offering.

This report analyzes the worldwide markets for Growth Factors (Blood and Tissue)

in Millions of US$. The major product segments analyzed are Blood Growth Factors, and Tissue Growth Factors. The sub product segments analyzed include Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region and product segment for the period of 2000 through 2010. The report profiles 43 companies including many key and niche players worldwide.

Contents Include:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.

1. Introduction

2. Market Overview

3. Market Dynamics

4. Outlook

5. Industry Issues

6. Competitive Trends

7. Growth Factors

8. Research and Development Highlights

9. Breakthroughs

10. Product Introduction

11. Product Launches in Recent Past

12. Recent Industry Activity

13. Strategic Corporate Developments in Recent Past

14. Focus on Select Global Players

15. Global Market Perspective

III. MARKET

1. The United States

2. Japan

3. Europe

4. Rest of World

IV. COMPETITION

Some Companies Mentioned include:

Amgen, Inc (USA)

Amrad Corporation Limited (Australia)

BD Biosciences (USA)

Berlex Laboratories, Inc (USA)

BioMimetic Pharmaceuticals, Inc (USA)

Biopharm GMBH (Germany)

Bio Surface Engineering Technologies, Inc (USA)

Bolder BioTechnology, Inc (USA)

Boston Life Sciences, Inc (USA)

Cambrex Corporation (USA)

Ceregene, Inc (USA)

Chiron Corporation (USA)

Cortex Biochem, Inc (USA)

Curis, Inc (USA)

Cytomedix, Inc (USA)

Dragon Pharmaceuticals, Inc (Canada)

F Hoffmann-La Roche Ltd (Switzerland)

Chugai Pharmaceutical Co, Ltd (Japan)

Genentech, Inc (USA)

FibroGen, Inc (USA)

Genemedix PLC (UK)

GenVec, Inc (USA)

Insmed, Inc (USA)

Invitrogen Corporation (USA)

Johnson & Johnson (USA)

Janssen-Ortho, Inc (Canada)

Ortho Biotech Products LP (USA)

Maxygen, Inc (USA)

NsGene A/S (Denmark)

Ortec International, Inc (USA)

Orthologic Corporation (USA)

PeproTech, Inc (USA)

CytoLab Ltd (Israel)

Prospec-Tany Technogene, Ltd (Israel)

QED Bioscience, Inc (USA)

R&D Systems, Inc (USA)

Receptron, Inc (USA)

Regeneron Pharmaceuticals, Inc (USA)

Sankyo Pharma, Inc (USA)

Santa Cruz Biotechnology, Inc (USA)

SCIL Proteins GmbH (Germany)

Selective Genetics (USA)

Sigma-Aldrich Corporation (USA)

Theratechnologies, Inc (Canada)

Wockhardt Ltd (India)

Xcellentis NV (Belgium)

Zymogenetics, Inc (USA)

For more information visit http://www.researchandmarkets.com/reports/c41501